Search research articles
Contact Us
Filters
Showing results (31-40 of 384) with videos related to
Page
of 39
Sort By:
Journal of Biomedicine & Biotechnology
|
June 16, 2012
Colorectal cancer chemoprevention by mesalazine and its derivatives
Carmine Stolfi, Francesco Pallone, Giovanni Monteleone
Cancers
|
December 17, 2024
Hepcidin Is a Valuable Therapeutic Target for Colorectal Cancer
Rachele Frascatani, Marco Colella, Giovanni Monteleone
Autoimmunity Reviews
|
June 19, 2013
Targets for new immunomodulation strategies in inflammatory bowel disease
Giovanni Monteleone, Roberta Caruso, Francesco Pallone
Clinical Science (London, England : 1979)
|
October 24, 2015
Pathogenic aspects and therapeutic avenues of intestinal fibrosis in Crohn's disease
Francesca Zorzi, Emma Calabrese, Giovanni Monteleone
Expert Opinion on Investigational Drugs
|
May 14, 2016
Tofacitinib for the treatment of ulcerative colitis
Roberta Izzo, Gerolamo Bevivino, Giovanni Monteleone
Discovery Medicine
|
October 17, 2009
Interleukin-21 in T cell-mediated diseases
Giovanni Monteleone, Massimiliano Sarra, Francesco Pallone
Journal of Clinical Medicine
|
February 27, 2026
Understanding Frailty in IBD: Implications for Clinical Outcomes and Multidisciplinary Care
Silvia Salvatori, Irene Marafini, Giovanni Monteleone
Journal of Ultrasound
|
April 6, 2024
Clinical and ultrasonographic evaluation of uninjured dominant shoulder in amateur rugby players vs a control group: a pilot study
Giovanni Monteleone, Alfonso Tramontana, Roberto Sorge
Nutrients
|
October 5, 2019
Impact of Food Additives on Gut Homeostasis
Federica Laudisi, Carmine Stolfi, Giovanni Monteleone
Journal of Crohn'S & Colitis
|
December 22, 2010
Th17 immune response in IBD: A new pathogenic mechanism
Flavio Caprioli, Francesco Pallone, Giovanni Monteleone
Page
of 39
Search research articles
Search
Showing results (31-40 of 384) with videos related to
Sort By:
Page
of 39
Journal of Biomedicine & Biotechnology
|
June 16, 2012
Colorectal cancer chemoprevention by mesalazine and its derivatives
Carmine Stolfi, Francesco Pallone, Giovanni Monteleone
Cancers
|
December 17, 2024
Hepcidin Is a Valuable Therapeutic Target for Colorectal Cancer
Rachele Frascatani, Marco Colella, Giovanni Monteleone
Autoimmunity Reviews
|
June 19, 2013
Targets for new immunomodulation strategies in inflammatory bowel disease
Giovanni Monteleone, Roberta Caruso, Francesco Pallone
Clinical Science (London, England : 1979)
|
October 24, 2015
Pathogenic aspects and therapeutic avenues of intestinal fibrosis in Crohn's disease
Francesca Zorzi, Emma Calabrese, Giovanni Monteleone
Expert Opinion on Investigational Drugs
|
May 14, 2016
Tofacitinib for the treatment of ulcerative colitis
Roberta Izzo, Gerolamo Bevivino, Giovanni Monteleone
Discovery Medicine
|
October 17, 2009
Interleukin-21 in T cell-mediated diseases
Giovanni Monteleone, Massimiliano Sarra, Francesco Pallone
Journal of Clinical Medicine
|
February 27, 2026
Understanding Frailty in IBD: Implications for Clinical Outcomes and Multidisciplinary Care
Silvia Salvatori, Irene Marafini, Giovanni Monteleone
Journal of Ultrasound
|
April 6, 2024
Clinical and ultrasonographic evaluation of uninjured dominant shoulder in amateur rugby players vs a control group: a pilot study
Giovanni Monteleone, Alfonso Tramontana, Roberto Sorge
Nutrients
|
October 5, 2019
Impact of Food Additives on Gut Homeostasis
Federica Laudisi, Carmine Stolfi, Giovanni Monteleone
Journal of Crohn'S & Colitis
|
December 22, 2010
Th17 immune response in IBD: A new pathogenic mechanism
Flavio Caprioli, Francesco Pallone, Giovanni Monteleone
Page
of 39